Industry’s ‘Regulatory Commitments’ Concept Draws FDA’s Interest
This article was originally published in The Gold Sheet
An industry team is talking up the potential role of what it’s calling ‘regulatory commitments’ to prospectively manage post-approval changes in a way that’s more consistent worldwide. FDA has responded with interest and is engaged in discussions on the idea.
You may also be interested in...
The ‘established conditions’ concept enshrined in the ICH Q12 draft guideline was the US FDA’s answer to the background information that has cluttered new drug applications in the quality-by-design era. But early indications are that it will amass information clutter of its own.
It remains uncertain whether a legal review by the European Commission that since June has delayed public consultation of draft ICH Q12 post-approval changes guideline can be resolved during this week's ICH meeting in Geneva.
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.